Advanced Practice Nurse
Prescribers with Davis Edge
6th Edition
• Author(s)Teri Moser Woo; Wendy
L. Wright
TEST BANK
▪ The Foundation
▪ Pharmacotherapeutics with Single Drugs
▪ Pharmacotherapeutics with Multiple Drugs
▪ Special Drug Treatment Considerations
,Question 1
A newly certified advanced practice registered nurse (APRN) joins a
primary care practice and asks the collaborating physician about
strategies to minimize prescribing errors. Which action is most
consistent with safe prescribing principles and current U.S. standards?
A. Prescribe medications primarily according to patient preference to
improve adherence.
B. Base prescribing decisions on an individualized assessment that
incorporates the patient's diagnosis, comorbidities, medication history,
allergies, current evidence, and ongoing monitoring.
C. Delegate medication reconciliation to office staff before every
prescription is written.
D. Limit medication changes during follow-up visits to reduce patient
confusion.
Correct Answer: B
Rationale: Safe prescribing requires integrating clinical assessment,
patient-specific factors, current evidence, medication history, allergies,
potential interactions, and an individualized monitoring plan.
Medication reconciliation remains the prescriber's responsibility even
when assisted by staff. Patient preference is important but should not
override evidence-based care. Necessary medication adjustments
should not be delayed solely to avoid confusion.
Question 2
An APRN evaluates a 72-year-old woman with hypertension, type 2
diabetes, chronic kidney disease, osteoarthritis, and depression. She
currently takes eight prescription medications and two over-the-
,counter supplements. Which prescribing principle should receive the
highest priority before initiating another medication?
A. Selecting the newest medication available
B. Evaluating the complete medication regimen for polypharmacy,
interactions, duplication, and deprescribing opportunities
C. Prescribing the lowest-cost medication regardless of efficacy
D. Avoiding all medication changes because multiple chronic illnesses
complicate management
Correct Answer: B
Rationale: Polypharmacy significantly increases the risk of adverse drug
events, drug-drug interactions, medication nonadherence, and
prescribing cascades. Comprehensive medication reconciliation and
consideration of deprescribing are essential before adding new
therapy. Cost is important but should not supersede efficacy and safety.
Question 3
A 48-year-old patient asks why the APRN is reviewing herbal
supplements before prescribing an antibiotic for cellulitis. What is the
best response?
A. Herbal products rarely influence prescription medications.
B. Herbal products are regulated identically to prescription
medications.
C. Herbal products may alter drug metabolism, increase adverse
effects, or reduce treatment effectiveness and should always be
reviewed.
, D. Herbal products only interact with cardiovascular medications.
Correct Answer: C
Rationale: Dietary supplements and herbal products may affect
cytochrome P450 enzymes, coagulation, absorption, or
pharmacodynamic effects, potentially causing clinically significant
interactions. Comprehensive medication histories should include
prescription drugs, OTC products, vitamins, and supplements.
Question 4
A patient with newly diagnosed hypertension asks why lifestyle
modification is being discussed before medication selection. Which
response best reflects evidence-based prescribing?
A. Lifestyle changes replace medications in nearly every patient.
B. Lifestyle modifications may improve disease control, reduce
medication requirements, and decrease long-term cardiovascular risk.
C. Lifestyle modification is recommended only for younger adults.
D. Lifestyle interventions are ineffective once hypertension has been
diagnosed.
Correct Answer: B
Rationale: Nonpharmacologic therapy remains an essential component
of chronic disease management and may reduce medication burden
while improving cardiovascular outcomes. Lifestyle measures
complement rather than universally replace pharmacotherapy.
Question 5